Symposium 2021
The 2021 GARROD Symposium Online
TARGET AUDIENCE
Physicians, Registered Nurses, Laboratory Technicians, Genetic Counsellors, Dieticians, Researchers, Clinical Specialists, and Students.
LEARNING OBJECTIVES
By the end of the activity participants will be able to:
Learn about new metabolic disease therapies including gene therapies, small molecule therapies, and enzyme replacement therapies.
Expand their knowledge of metabolic diseases in Indigenous populations.
Learn about metabolic diseases in Amish, Mennonite and Hutterite populations.
Share experiences in providing metabolic genetic services to new immigrants.
*Please note: 25% of the scientific program will be interactive.
Schedule
START:
5 May, 2021 at 10:45 AM
-
END :
7 May, 2021 at 5:45 PM
Location
Virtual Conference
Contact Info
Evaluation Day 1 May 5, 2021
Day 1 Overall Evaluation
12:00 – 12:15
Welcome & Introduction - Murray Potter and Andreas Schulze
Session I – New Therapies- Part 1
12:15 – 13:00
DNA: From Diagnosis to Treatment the Modern Age of Diagnosing and Treating Metabolic Diseases Evaluate Dr. Aneal Khan
13:00 – 13:45
New Aspects of Fabry Disease Including Treatment With Pharmacological Chaperones Evaluate Dr. Daniel G. Bichet
Session II – Unique Populations
14:45 – 15:30
Caring for Children and Youth to Canada: Resources and considerations for Health Care Providers Evaluate Dr. Andrea Hunter
15:30 – 16:00
Genetic Research with Manitoba’s Hutterite and Mennonite Communities: Navigating Tradition and Innovation Evaluate Dr. Cheryl Rockman-Greenberg
16:00 – 16:30
Working with the Old Order Amish and Mennonite Populations: Successes and Challenges in the Delivery of Healthcare and Targeted Genetic Testing of Newborns and Adults Evaluate Dr. Victoria Mok Siu
Evaluation Day 2 May 6, 2021
Day 2 Overall Evaluation
Session III – New Therapies Part 2
12:15 – 13:00
Novel Enzyme Substitution Therapy for Adults with Phenylketonuria (PKU) Evaluate Dr. Cary O. Harding
13:00 – 13:45
Nutrition Management of Patients receiving enzyme therapy for PKU Evaluate Dr. Krista Viau
Session IV – Indigenous Health
14:45 – 15:30
Protective or Deleterious? the Unresolved Debate of the Effect of the CPT1A p.P479L Variant on Inuit and West Coast First Nations Health Evaluate Dr. Laura Arbour – Sorcha Collins
15:30 – 16:15
Pyruvate Carboxylase Deficiency in Indigenous Populations: Prevalence and Phenotype Evaluate Dr. Aziz Mhanni
Evaluation Day 3 May 7, 2021
Session V – Adult Metabolics
12:15 – 12:45
Neurometabolic disorders in adults: Focus on mitochondrial disease, fatty acid oxidation defects, Pompe disease and glycogen storage diseases affecting muscle (ME) Evaluate Dr. Mark Tarnopolsky
12:45 – 13:15
Unique Management Considerations in Adult Patients with Inborn Errors of Metabolism Evaluate Dr. Hanna Faghfoury
13:15 – 13:45
Dietary Management: Considerations for Adults Evaluate Heather Bell
14:45 – 15:30
Polygenic Effects in Disease Evaluate Dr. Robert Hegele
15:30 – 15:45
GM2 Gangliosidosis: Canadian Perspective Evaluate Dr. Jagdeep S. Walia
ACCREDITATION STATEMENT
McMaster University, Continuing Professional Development Office (CPD) is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME) to provide CFPC Mainpro+ and RCPSC Maintenance of Certification (MOC) study credits for Continuing Medical Education.
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada and approved by McMaster University Continuing Professional Development Office (CPD) for up to 8.75 MOC Section 1 credits.
The American Medical Association: Through an agreement between The Royal College of Physicians and Surgeons of Canada and The American Medical Association, Physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at:
www.ama-assn.org/go/internationalcme